Dr. Ruckman provides scientific consulting and technical writing services in the areas of Analytical Methods Development, cGMP Compliance, Clinical Trial Auditing and FDA submissions.

Dr. Ruckman has a strong background in drug discovery research in both the biotechnology and traditional pharmaceutical company environments. Following her Ph.D., Dr. Ruckman joined NeXagen, Inc., a start-up biotechnology company in Boulder, CO. During her tenure at the company, NeXagen grew into NeXstar Pharmaceuticals, Inc., a worldwide, vertically integrated pharmaceutical company. Dr. Ruckman served for 6 years as a senior member of the research staff at NeXagen and NeXstar, working on the discovery and development of therapeutic agents for autoimmune disease, immune suppression, hyperproliferative disorders, and cancer. Dr. Ruckman was a core member of the research team that discovered and initiated development of NX1838, a nucleic-acid-based ligand to vascular endothelial growth factor, which NeXstar carried through Phase I clinical trials. NX1838 (now EYE001) was licensed to EyeTech Pharmaceuticals and is presently in pivotal Phase III studies for age-related macular degeneration.

Following the merger of NeXstar with Gilead Sciences, Inc., Dr. Ruckman assumed a managerial role, leading a team of scientists working in the area of traditional pharmaceutical drug discovery for cancer indications. She served for over two years as a team member and team leader on projects directed at the discovery of novel cytostatic and anti-angiogenic agents.

Dr. Ruckman received her B.S. degrees from the University of Utah in Biology and Chemistry while working as an undergraduate research assistant. Her graduate research on bacteriophage T4 mRNA processing was conducted at the University of Colorado in the Department of Molecular, Cellular and Developmental Biology. During her graduate training, Dr. Ruckman was supported by a National Science Foundation Pre-Doctoral Fellowship. She was also awarded a Chateaubriand Fellowship from the French governmental research organization that supported a 6 month collaborative research project at the Centre de Génètique Moléculaire in Gif-sur-Yvette, France.

Dr. Ruckman is the author or co-author of numerous peer-reviewed publications and patents. Her 21 years of laboratory experience include peptide and protein purification, extensive work with nucleic acids, bacterial, bacteriophage, and mammalian cell culture, biochemical assays, and a diversity of standard molecular biological techniques. Dr. Ruckman’s experience in the pharmaceutical industry provides her with a strong sense of the drug discovery and drug development process and the path from benchtop to bedside. As a Scientific Consultant at CBR International, Dr. Ruckman provides valuable expertise in the areas of scientific review, product and methods development, validation protocol design, technical writing, and detailed compliance audits.

Consistent, thorough and up-to-date analysis of your evolving needs is just the beginning of our commitment to your program. For a comprehensive assessment of your program requirements, please contact us by calling (720) 746-1190 or by email at info@cbrintl.com.